• HOME
  • NEWS
    • BIOENGINEERING
    • SCIENCE NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • FORUM
    • INSTAGRAM
    • TWITTER
  • CONTACT US
Thursday, February 25, 2021
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
    • BIOENGINEERING
    • SCIENCE NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • FORUM
    • INSTAGRAM
    • TWITTER
  • CONTACT US
  • HOME
  • NEWS
    • BIOENGINEERING
    • SCIENCE NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • FORUM
    • INSTAGRAM
    • TWITTER
  • CONTACT US
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

MICROB-PREDICT — €15 million EU funded microbiome research project kicks off

Bioengineer by Bioengineer
February 1, 2019
in Health
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Developing personalised targets for treatment of decompensated cirrhosis and acute-on-chronic liver failure (ACLF)

Barcelona, Spain, 1 February 2019 – An EU Horizon 2020-financed project investigating methods to better understand the role of the microbiome to help stratify patient health care and treatment of decompensated cirrhosis and ACLF officially commenced last month. The innovative endeavour, known as MICROB-PREDICT, involves a 22-member multinational and multidisciplinary consortium of world-leading microbiome specialists, clinical experts, and patient organisations. MICROB-PREDICT is an acronym for “MICROBiome-based biomarkers to PREDICT decompensation of liver cirrhosis and treatment response”. Cirrhosis is the cause of 1.2 million deaths worldwide annually . It is estimated that less than 10% of ongoing studies in the field are focused on decompensated cirrhosis and ACLF . As a result, treatment options for patients are lacking considerably.

MICROB-PREDICT & the gut-liver-axis

The microbiome plays a critical role in the development and severity of cirrhosis, which is a major cause of morbidity and mortality worldwide. “One of our aims is to find the microbiome signatures of decompensation of cirrhosis and predict the development of ACLF. Moreover, this project will develop point-of-care devices to predict the response to specific treatments in these patients. The project has the potential to change the clinical practice towards more personalized medicine,” says Prof. Jonel Trebicka, scientific coordinator of the MICROB-PREDICT consortium.

Potential for new treatment strategies

The project will base the development of biomarkers on high-quality data from three existing EU-funded projects (GALAXY, LIVERHOPE, and PREDICT). The knowledge gained throughout the 75 month project will contribute to the development of improved and potentially personalized therapies for patients suffering from cirrhosis and ACLF. A basic website about the project is already online (http://www.microb-predict.eu), and a more extensive project website will be launched in the coming months.

The 22 partners in the MICROB-PREDICT consortium coordinated by EF-CLIF are:

  • Academisch Ziekenhuis Leiden (Leiden University Medical Center) (LUMC)

  • Biobyte Solutions GmbH (Biobyte)

  • Commissariat à l’Energie Atomique et aux Energies Alternatives (CEA)

  • concentris research management GmbH (concentris)

  • Debreceni Egyetem (University of Debrecen) (UNIDEB)

  • European Association For The Study of the Liver (EASL)

  • European Foundation For The Study of Chronic Liver Failure (EF-CLIF)

  • European Liver Patients Association (ELPA)

  • European Molecular Biology Laboratory (EMBL)

  • Fundacio Clinic Per A La Recerca Biomedica (FCRB)

  • Fundacio Institut Catala De Nanociencia i Nanotecnologia (ICN2)

  • Institut National De La Recherche Agronomique (INRA)

  • Johann Wolfgang Goethe-Universität Frankfurt Am Main (GUF)

  • Katholieke Universiteit Leuven (KU Leuven)

  • King’s College London (KCL)

  • Max-Planck-Gesellschaft zur Foerderung der Wissenschaften e.V. (MPG)

  • Odense Universitetshospital (OUH)

  • Universitat de Barcelona (UB)

  • Universitetet I Oslo (UiO)

  • University College London (UCL)

  • University of Copenhagen (UCPH)

  • Vaiomer SAS (Vaiomer)

###

1 – Murray CJ, Atkinson C, Bhalla K, Birbeck G, Burstein R, Chou D, et al (2013). The state of US health, 1990-2010: burden of diseases, injuries, and risk factors. JAMA; 310: 591-608.

2 – Zutshi Y (2015). Liver Disease Treatments: The Global Market. BBC Research; PHM057C.

Media Contact
Margaret Walker
[email protected]
44-077-471-21175
https://mailchi.mp/easloffice/press-release-microbpredict-01022019

Tags: GastroenterologyInternal MedicineLiverMedicine/Health
Share12Tweet7Share2ShareShareShare1

Related Posts

IMAGE

UTEP survey reveals hidden health and wellness benefits of COVID-19 pandemic

February 25, 2021
IMAGE

A cat of all trades

February 25, 2021

Study: Bladder cancer is more advanced in South Texas

February 25, 2021

New radiology research shows promising results for focused ultrasound treatment of Alzheimer’s

February 25, 2021

Leave a Reply Cancel reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

POPULAR NEWS

  • IMAGE

    Terahertz accelerates beyond 5G towards 6G

    637 shares
    Share 255 Tweet 159
  • People living with HIV face premature heart disease and barriers to care

    81 shares
    Share 32 Tweet 20
  • Global analysis suggests COVID-19 is seasonal

    37 shares
    Share 15 Tweet 9
  • HIV: an innovative therapeutic breakthrough to optimize the immune system

    35 shares
    Share 14 Tweet 9

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Tags

Chemistry/Physics/Materials SciencescancerInfectious/Emerging DiseasesClimate ChangeCell BiologyMaterialsGeneticsPublic HealthMedicine/HealthTechnology/Engineering/Computer ScienceEcology/EnvironmentBiology

Recent Posts

  • Social dilemma follows 2018 eruption of Kilauea volcano
  • UTEP survey reveals hidden health and wellness benefits of COVID-19 pandemic
  • Scientists investigated more thoroughly Walker breakdown in 3D magnetic nanowires
  • Smaller plates help reduce food waste in campus dining halls
  • Contact Us

© 2019 Bioengineer.org - Biotechnology news by Science Magazine - Scienmag.

No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

© 2019 Bioengineer.org - Biotechnology news by Science Magazine - Scienmag.

Welcome Back!

Login to your account below

Forgotten Password?

Create New Account!

Fill the forms below to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In